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Glutathione-S-transferase Pi1 (GSTP1) and multidrug resistance protein 1 (MRP1) are overexpressed in melanoma, a skin cancer
notoriously resistant to all current modalities of cancer therapy. To investigate the involvement of these detoxifying enzymes in the
drug resistance of melanoma, an inducible (Tet-Ont system) antisense (AS) RNA strategy was used to specifically inhibit GSTP1
expression in A375 cells, a human melanoma cell line expressing high levels of GSTP1 and MRP1. Stable transfectant clones were
established and analysed for GSTP1 inhibition by AS RNA. The clone A375-ASPi1, presenting a specific 40% inhibition of GSTP1
expression in the presence of doxycycline, was selected. Lowering the GSTP1 level significantly increased (about 3.3-fold) the
sensitivity of A375-ASPi1 cells to etoposide. Inhibitors of glutathione synthesis (BSO), GSTs (curcumin, ethacrynic acid), and also of
MRPs (MK571, sulphinpyrazone) improved the sensitising effect of GSTP1 AS RNA. All these inhibitors had stronger sensitising
effects in control cells expressing high GSTP1 level (A375-ASPi1 cells in the absence of doxycycline). In conclusion, GSTP1 can act in
a combined fashion with MRP1 to protect melanoma cells from toxic effects of etoposide.
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Development of drug resistance is a key element in the failure of
chemotherapy treatment. Melanoma, the most aggressive form of
skin cancer, is notoriously resistant to all current modalities of
cancer therapy (Helmbach et al, 2001). A large set of genetic,
functional and biochemical studies suggest that melanoma cells
become insensitive to a variety of chemotherapeutic drugs by
exploiting their intrinsic resistance to apoptosis and by repro-
gramming their proliferation and survival pathways during
melanoma progression. Among the systems potentially involved
in melanoma cell chemoresistance, the overexpression of glu-
tathione S-transferases (GSTs) and multidrug resistance proteins
(MRPs) may play an important role (Schadendorf et al, 1995b;
Moral et al, 1997; Serrone and Hersey, 1999).
Glutathione-S-transferases are a family of phase II detoxification
enzymes that catalyse the conjugation of glutathione (GSH) to a
wide variety of electrophilic compounds, including anticancer
drugs but also carcinogens or mutagens (Tew, 1994; Townsend and
Tew, 2003). Glutathione-S-transferases are divided into two
distinct super-families: the membrane-bound microsomal and
the cytosolic GSTs (Townsend and Tew, 2003). Human cytosolic
GSTs are highly polymorphic and can be divided into six classes
(namely alpha, Mu, Pi, Theta, Omega and Zeta) (Townsend and
Tew, 2003).
The alpha, Pi and Mu classes of GSTs are the most studied and
the most implicated in cellular resistance (Tew, 1994). Thus,
tumours (Schisselbauer et al, 1990) or cell lines (Tew, 1994; Hayes
and Pulford, 1995) show an increased GST level after development
of drug resistance, cancer cells transfected with GSTs can express a
drug resistance (Moscow et al, 1989; Manoharan et al, 1991;
Morrow et al, 1998; Depeille et al, 2004) and the inhibition by
antisense (AS) gene of endogenous GSTP expression reduces drug
resistance (Ban et al, 1996). The first mechanism by which GSTs
can confer drug resistance is direct detoxification. Usually,
electrophiles are made less reactive by conjugation with glu-
tathione, and the conjugates are thought to be less toxic to the cell.
More recently, a plausible second role of GSTs in the development
of drug resistance through the inhibition of the mitogen-activated
protein (MAP) kinase pathway by protein: protein interactions was
evoked (Adler et al, 1999; Townsend and Tew, 2003). However,
some other investigators have not found associations between
cellular resistance to anticancer agents and expression of GSTs
(Townsend et al, 1992). Thus, the role of GSTs in the protection of
cells against anticancer drugs remains equivocal.
The overexpression of GSTs is not always sufficient to confer
significant protection from the electrophiles. Thus, it has been
shown that GSTs must be coexpressed with MRPs, particularly
MRP1 and MRP2, to protect cells from anticancer agents (Morrow
et al, 1998; Harbottle et al, 2001; Depeille et al, 2004; Smitherman
et al, 2004). Multidrug resistance protein 1 and MRP2 belong to the
nine members family of ABC transporters, discovered by Cole et al
(1992), that are responsible for the active transport across
biological membrane of structurally diverse lipophilic anions
(Borst et al, 1999; Kruh and Belinsky, 2003). Multidrug resistance
protein 1, MRP2 and MRP3 have overlapping substrate specificity,
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sincluding glutathione-conjugates (Keppler et al, 2000). Multidrug
resistance protein 4 an MRP5 are involved in nucleotide efflux
(Wijnholds et al, 2000). Initially, MRP1 and MRP2 have been
shown to confer resistance to various drugs of natural origin,
including anthracyclines, vinca alkaloids and epipodophyllotoxins
(Borst et al, 1999). Then, the requirement of GSH for MRP1-
mediated cellular efflux of some natural products was demon-
strated (Rappa et al, 1997). Finally, it was reported that
detoxification of anticancer agents implicated a combined action
of GSTs and MRPs (Morrow et al, 1998; O’Brien et al, 2000;
Harbottle et al, 2001; Depeille et al, 2004).
Human melanoma expresses high levels of GSTP1 (Moral et al,
1997) and MRP1 (Schadendorf et al, 1995b). The aim of this study
was to investigate the role of GSTP1 and MRPs in resistance of this
skin tumour to drugs. To address this question, an inducible AS
RNA strategy we used to, in a tetracycline-controlled fashion,
specifically inhibit GSTP1 expression in the GSTP1 and MRP1
expressing A375 human melanoma cells. The efficacy of the GST
inhibition (mRNA and protein expression, enzyme activity) by AS
RNA was quantified in the cell lines. The effects of the lowering of
GSTP1 expression level on drug sensitivity were assessed. Finally,
GST and MRP inhibitors were used to confirm the results obtained
using AS approach.
MATERIALS AND METHODS
Drugs and chemicals
Geneticin and hygromycin were from Life Technologies (Cergy
Pontoise, France). [
3H]-etoposide (0.654Cimmol
 1) was pur-
chased from Moravek Biochemicals (Brea, CA, USA). Doxycycline
was from Clontech (St Quentin Yvelines, France). MK571 was from
Biomol International (Le Perray en Yvelines, France) (10mM in
H2O). All other drugs were from Sigma (St Quentin-Fallavier,
France). Stock solutions were vincristine (100mM in H2O),
doxorubicin (3.7mM in H2O), mitomycin C (10mM in H2O),
chlorambucil (100mM in ethanol), melphalan (100mM in acidified
ethanol), 1-chloro-2,4-dinitrobenzene (CDNB) (100mM in PBS),
glutathione (GSH) (100mM in H2O), cisplatin (5mM in 0.9% NaCl),
mitoxantrone (5mM in dimethyl sulphoxide), etoposide (5mM in
dimethyl sulphoxide), curcumin (2.5mM ethanol), ethacrynic acid
(2.5mM in H2O), sulfinpyrazone (200mM in dimethyl sulphoxide)
and D,L-buthionine-[S,R]-sulphoximine (BSO) (5mM in H2O).
The cDNA encoding on one hand human GSTA1, GSTP1 and
GSTM1, on the other hand human MRP1 and MRP2 were kindly
provided by Dr CS Morrow (Wake Forest University School of
Medicine, Winston-Salem, USA) and Pr D Keppler (DKFZ,
Heidelberg, Germany), respectively.
Construction of a GSTP1 AS vector
The full-length cDNA encoding human GSTP1 was amplified by
PCR using standard procedures and the following primers: ASPi-
front 50-GATATCGCGGCCGCATGCCGCCCTACACCGTGGTC-30,
and ASpi-reverse 50-GGATCCACGCGTTCACTGTTTCCCGTTGC
CATT-30. Amplified sequence and pTRE2hyg (Clontech, St
Quentin Yvelines, France) were digested by BamHI and EcoRV
(Eurogentec, Angers, France). Both of these processed fragments
were then ligated with T4 ligase (Life Technologies, Cergy
Pontoise, France), and a clone was selected in which the GSTP1
cDNA was inserted in the reverse direction. This clone was named
ppTRE-ASPi.
Cells lines
A375 human malignant melanoma (MM) cells (CRL-1619, Amer-
ican Type Culture Collection, Manassas, VA, USA) were grown at
371C in a fully humidified 5% CO2 atmosphere in DMEM
supplemented with 10% Tet-system approved foetal bovine serum
(Clontech, St Quentin Yvelines, France). A375 cells expressing
human GSTP1 inducible AS RNA were established by transfection
(LipofectAMINEt, Invitrogen, Cergy Pontoise, France) of A375-wt
cells with Tet-Ont gene expression system (Clontech, St Quentin
Yvelines, France) consisting of two vectors. First, cells were
transfected with pTet-On, expressing reverse tetracycline-con-
trolled transactivator (rtTA), and clones were selected for geneticin
(1mgml
 1) resistance and for rtTA expression level (luciferase
assay, according to manufacturer’s instruction). Then clones
were transfected with ppTRE-ASPi, a pTRE2hyg vector containing
the cDNA encoding the human GSTP1 AS RNA and selected
for antibiotic resistance (1mgml
 1 geneticin and 0.4mgml
 1
hygromycin). One clone, namely A375-ASPi1, presenting a
specific and significant inhibition of GSTP1 expression in the
presence of doxycycline (0.2mgml
 1, 24h) was used for further
analysis.
Analysis of GST and MRP expression
Reverse transcription polymerase chain reaction Extraction of
total cellular RNA was carried out using Trizolt reagent
(Invitrogen, Cergy Pontoise, France) and expression was analysed
by reverse transcription polymerase chain reaction (RT—PCR)
using standard procedures and specific primers (Depeille et al,
2004). Positive controls were either plasmids containing the coding
sequences for GSTs (A1, P1 and M1) and MRPs (1 and 2), or Caco-
2 cells for MRP3 (Depeille et al, 2004). PCR products were run on
agarose gels supplemented with ethidium bromide and visualised
by ultraviolet illumination. Band intensities were quantified by
densitometry analysis using Bio1D software (Vilber Lourmat,
Marne La Valle ´e, France).
Quantitative real-time PCR Extraction of total cellular RNA was
carried out using RNA easy kit (Qiagen, Courtabœuf, France)
according to the manufacturer’s procedure. Reverse transcription
was done using standard procedure. Glutathione-S-transferase
P1 expression was determined by real-time PCR on a Light-
Cycler instrument (Roche Diagnostics, Meylan, France) using a
SYBRGreen
s fluorescent dye, which binds to the double-stranded
DNA yielding fluorescence. The cDNA amplication was performed
in 40 cycles as follows: initial predenaturation 951C/10min,
denaturation 951C/10s, annealing 581C/6s, extention 721C/10s.
All the steps were performed in Faststart DNA Master SYBR
Green I mix (Roche Diagnostics, Meylan, France) using specific
primers (0.5mM) (Depeille et al, 2004) and 4mM MgCl2. The
specificity of amplication was checked using post-PCR melting
curves analysis with Tm determination. During exponential phase
of PCR reaction, the crossing threshold (CT) was determined
for each amplification curves. CAL1-m1 cell line (Depeille et al,
2004) was used as calibrator. All results were normalized with
beta-actin gene and expressed as ratios related to GSTP1
expression in the calibrator. The relative quantification ratio was
evaluated using quantification based on CT method with an
efficiency (E) correction:
Normalizedratio ¼E
DCTGSTP1ðcalibrator sampleÞ
GSTP1
 E
DCTbeta-actinðsample calibratorÞ
beta-actin
Western blot analysis The expression of GSTs in A375 cells was
investigated as previously described (Depeille et al, 2004). Briefly,
cells treated or not with doxycycline (0.2mgml
 1, 24h) were
homogeneized in lysis buffer. After centrifugation cytosolic
proteins (20mg) were separated by 12% SDS–polyacrylamide gel
electrophoresis and electroblotted onto nitrocellulose membrane.
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sThe membranes were blocked in 10% milk in PBS-Tween followed
by incubation with rabbit polyclonal primary antibodies anti-GST
alpha or mu and with mouse monoclonal primary antibody anti-
GST Pi 1:500 (Novocastra-Tebu, Le Perray en Yvelines, France), or
mouse monoclonal primary antiboby anti-beta-actin 1:2000
(Sigma, St Quentin Fallavier, France). Then, membranes were
incubated with anti-species peroxydase-conjugated secondary
antibodies 1:5000 (Sigma, St Quentin Fallavier, France) and
visualised using enhanced chemiluminescence (ECL) reagents
(Amersham Biosciences, Saclay, France). Band intensities were
quantified by densitometry analysis using Bio1D software (Vilber
Lourmat, Marne La Valle ´e, France).
To study MRP expression, cells were lysed on ice in RIPA
buffer (20mM Tris pH 7.5, 150mM NaCl, 1% Triton X-100, 1%
sodium desoxycholate, 0.1% SDS) supplemented with fresh 1mM
DTT, 2mM NaF and protease inhibitor cocktail (Sigma) (Depeille
et al, 2004). The lysates were centrifuged and the supernatants
proteins (100mg) were separated by 7% SDS–polyacrylamide
gel electrophoresis and electroblotted at 41C onto nitrocellulose
membrane. The membranes were blocked in 5% milk in PBS-
Tween followed by incubation with mouse monoclonal primary
antibodies anti-MRP1, anti-MRP2 (Monosan-Tebu, Le Perray
en Yvelines, France) and anti-MRP3 (Chemicon international,
Mundolsheim, France). Then, membranes were incubated with
anti-mouse peroxydase-conjugated secondary antibodies (Sigma,
St Quentin Fallavier, France) and ECL detection as described
above.
Functional analysis of GST and MRP activities Evaluation of GST
activity was performed as follows. Cells treated or not with
doxycycline were lysed in PBS pH 6.5 by three freezing (in liquid
nitrogen)/defrosting (371C) cycles and cytosols were recovered by
centrifugation for 10min at 4000g and 41C. The total GST activity
was measured using CDNB as substrate (Depeille et al, 2004).
Conjugation of reduced GSH to CDNB at 251C and pH 6.5 was
monitored spectrophotometrically at 340nm.
The evaluation of MRP functional activity was assessed by
studying [
3H]-etoposide accumulation as described (Decleves et al,
2002). Cells, plated onto 12-microwell plates pretreated or not with
doxycycline (0.2mgml
 1, 24h), were incubated for 1h at 371C with
5mM [
3H]-etoposide in culture medium. After washing with PBS,
cells were incubated at 371C for 3h in the absence (control) or
presence of inhibitors (2mM sulphinpyrazone, 30mM MK571, 30mM
curcumin, 3.3mM ethacrynic acid). Then, cells were washed with
ice-cold PBS to eliminate the extracellular tritiated drug and lysed
with 500ml of 0.1 N NaOH. Intracellular [
3H]-etoposide concentra-
tion was determined by b-scintillation counting and normalised to
protein counting.
Cytotoxicity assays The effect of anticancer agents on cell
viability was assessed using the neutral red assay as previously
described (Evrard et al, 1999; Depeille et al, 2004). Briefly, aliquots
of cell suspension (10
4cells well
 1) were seeded in 96-well
microtiter plates and incubated for 24h at 371C in the presence
or absence of doxycycline (0.2mgml
 1). Then, cells were exposed
to mitomycin, chlorambucil, cisplatin, mitoxantrone and melpha-
lan for 1h at 371C (150ml in fresh medium per well, eight wells per
agent concentration). For doxorubicin, vincristine and etoposide,
cells were exposed to drug for 4h at 371C in fresh medium
supplemented with 1% fetal calf serum (FCS). When used, GST or
MRP inhibitors were added 15min before exposure to anticancer
drugs. After 72h incubation, cells were washed and a neutral red
solution (33mgml
 1) was added. After 3h at 371C, cells were
washed and destained with glacial acetic acid (1%) – ethanol (50%)
(vv
 1). Absorbances at 540nm were measured using a microplate
reader (Labsystems Multiscan MS). The effect of the drugs on cell
survival was expressed as percentage of viability of treated-cells
compared with control cells.
RESULTS
Characterization of cell lines
A375 MM cells (ATCC CRL1619) were chosen to assess the effects
of the inhibition of GSTP1 expression on drug resistance. Reverse
transcription polymerase chain reaction and Western blot experi-
ments were designed to study the expression of GSTs and MRPs in
A375 cells. As shown in Figure 1, high level of GST pi1 (GSTP1)
and low level of GST mu1 (GSTM1) were detected in these cells,
whereas GST alpha1 (GSTA1) was not found. Additionally MRP1
and MRP3, two ABC transporters involved in glutathione
conjugate efflux (Keppler et al, 2000; Kruh and Belinsky, 2003)
were identified (Figure 1). The expression level of MRP1 was
higher than that of MRP3. In contrast MRP2, having overlapping
substrate specificity with MRP1 (Smitherman et al, 2004), was not
detected. Thus, A375 cells were a good model to study, by RNA AS
Doxycycline
-Actin
GSTP1
GSTA1
GSTM1
MRP1
MRP2
MRP3
Doxycycline
-Actin
GSTP1
GSTA1
GSTM1
MRP1
MRP2
MRP3
Control
A375-ASPil A375-wt
++ − −
A375-ASPil A375-wt
++ − −
A
B
Figure 1 Expression of GSTs and MRPs in A375 cell lines. Levels of
GSTs and MRPs mRNA (A) and (B) were determined by RT–PCR and
Western blot, respectively, as described under ‘Materials and Methods’.
Examined are cellular mRNA (4ng each lane) and proteins (20mg and
100mg each lane for GSTs and MRPs, respectively) from parental cells
(A375-wt) and cells transfected with pTet-On and ppTRE2-ASPi (A375-
ASPi1). Experiments were made in the presence (þ) or absence ( )o f
doxycycline (0.2mgml
 1, 24h). Positive controls were plasmids encoding
GSTs (A1, M1, P1) and MRPs (1 and 2) or cDNA from Caco-2 cells for
MRP3 for PCR experiments. b-Actin was used as a standardisation control
in two detection experiments.
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sstrategy, the combined effects of GSTP1 and MRPs in MM
chemoresistance.
As described in Materials and Methods, the controlled expres-
sion of GSTP1 AS RNA in A375 cells was obtained by using the
Tet-Ont gene expression system. A375 cells were doubly
transfected with two expression vectors: first with pTetOn
containing the reverse rtTA, then with ppTRE-ASPi encoding
human GSTP1 AS RNA, and double stable transfectants were
selected for antibiotic resistance. The expression profiles of GSTs
and MRPs in the double transfectant clones and in the parental
A375-wt cells were similar (Figure 1).
Next, the clones were analysed for inhibition level of GSTP1 by
AS RNA expressed under tetracycline control. The clone A375-
ASPi1 displayed, in the presence of doxycycline (0.2mgml
 1, 24h),
a specific 40% inhibition of GSTP1 mRNA and protein expression
(Figure 1 and Table 1), and a significant decrease (about 40%) of
total GST activity (Figure 2). Neither the expression of the other
GSTs (A1 and M1) nor that of the MRPs was affected by
doxycycline treatment in these cells (Figure 1).
To study the duration of the GSTP1 inhibition after doxycycline
treatment, A375-ASPi1 cells were lysed either immediately or 7 to
20h after removal of the tetracycline from the culture medium, and
lysates were assayed for GSTP1 immunoreactivity. As shown in
Figure 3, the 40% inhibition of GSTP1 level was still observed 7h
after removal of the doxycycline, whereas the expression level went
back to basal value after a 20h incubation period. Thus, the
lowering of GSTP1 by AS RNA remained significant during the
incubation time (at the most 4h) of anticancer drugs in
cytotoxicity assays. A375-ASPi1 cells presenting a tetracycline-
controlled, significant, specific and lasting inhibition of GSTP1
expression were selected for further analysis.
Effect of GSTP1 inhibition on the drug sensitivity of A375
cells
We first studied the effects of GSTP1 inhibition by AS RNA on the
drug sensitivity of A375 cell-ASPi1 cells with the use of the neutral
red uptake assay. In our experimental conditions, the 24h
preincubation in the presence of 0.2mgml
 1 doxycycline had no
effect on cell viability. Anticancer drugs belonging to different
therapeutic classes were tested: alkylating agents (chlorambucil,
melphalan, mitomycin C, cisplatin), topoisomerase II inhibitors
(doxorubicin, mitoxantrone and etoposide) and vinca alkaloid
(vincristine). The corresponding data are summarised in Table 2.
Inhibition of GSTP1 significantly decreased the resistance of A375-
ASPi1 melanoma cells to etoposide (about three-fold) (Figure 4),
but had no significant effect on relative resistance to the other
agents tested. Moreover, the cytotoxicity profiles of parental A375-
wt cells with or without doxycycline pretreatment were similar
each other (data not shown), and were similar to that of
A375-ASPi1cells in the absence of doxycycline (A375-ASPi1
( ))
(Table 2).
To confirm the etoposide sensitising effect of the AS RNA-
mediated reduction of GSTP1 expression in A375-ASPi1 cells, we
tested whether inhibition of GST activity by the GST inhibitors
curcumin (Harbottle et al, 2001) and ethacrynic acid (O’Dwyer
et al, 1991) would also sensitise these cells. As shown in Figure 4
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Figure 2 GST activities in A375-ASPi1 cells. Cytosolic proteins were
extracted from A375-ASPi1 cells incubated in presence (þ) or absence
( ) of doxycycline (0.2mgml
 1, 24h) and assessed for their ability to
conjugate CDNB to GSH as described in ‘Material and Methods’.
Glutathione-S-transferase activities, expressed as nmolmin
 1 CDNB
conjugated with GSH per mg of cytosolic protein, are means7s.e.m. of
at least three separate experiments. **Po0.01 according to Student’s t-test
comparing values obtained in studied cells with those obtained in A375-
ASPi1 cells in the absence of doxycycline.
Table 1 Level of GSTP1 mRNA in A375-ASPi1 cells
Cell lines GSTP1 mRNA normalized ratios
CAL1-m1 1.0
A375-ASPi1
( ) 1.170.1
A375-ASPi1
(+) 0.670.04
Exponents
(+) and
( ) indicate that A375-ASPi1 cells were pretreated in the presence
or absence of doxycycline, respectively. CAL1-m1 cell line was used as calibrator.
GSTP1 mRNA normalized ratios were obtained as described in ‘Material and
Methods’. Data are means from three separate experiments.
− + Doxycycline
0h +7h +20h 0h
GSTP1
-Actin
Figure 3 Duration of GSTP1 inhibition after doxycycline removal. Level
of GSTP1 protein inhibition was determined by Western blot, as described
under ‘Materials and Methods’. Examined are cytosolic proteins (20mg each
lane) from A375-ASPi1 cultured in presence (þ) or absence ( )o f
doxycycline (0.2mgml
 1, 24h). Lane 1, A375-ASPi1 were cultured in
absence of doxycycline, corresponding to control cell line. Lanes 2, 3 and 4,
A375-ASPi1 were cultured in presence of doxycycline during 24h and
lysed immediately, 7 and 20h after doxycycline removal. b-Actin was used
as a standardisation control in detection experiment.
Table 2 Effects of the inhibition of GSTP1 expression by antisense RNA
on cellular sensitivities to anticancer drugs
Anticancer drugs Fold sensitisation
Cisplatin 0.83
Chlorambucil 1.11
Melphalan 0.9
Etoposide 3.33***
Mitoxantrone 0.83
Doxorubicine 1.11
Vincristine 1
Fold sensitisation¼IC50 of A375-ASPi1
( )/IC50 of A375-ASPi1
(+). Exponents
(+) and
( ) indicate that cells were pretreated in the presence or absence of doxycycline,
respectively. Data are means from at least three separate experiments. ***Po0.001
(Student’s t-test).
GSTP1 and MRP1 in etoposide resistance
P Depeille et al
219
British Journal of Cancer (2005) 93(2), 216–223 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sand Table 3, both inhibitors significantly amplified (about five-fold
and two-fold, respectively) the AS RNA-mediated sensitisation of
doxycycline-treated A375-ASPi1
(þ) cells. The inhibitors had
stronger (about 11-fold and 18-fold, respectively) sensitising
effects in A375-ASPi1
( ) control cells expressing high GSTP1 level.
The requirement of glutathione in the GSTP1-mediated protective
effect was confirmed by using BSO, an inhibitor of glutathione
synthesis (Bailey, 1998). In fact, glutathione depletion significantly
increased the etoposide sensitivity of A375-ASPi1 cells (Table 2).
None of the inhibitors used (curcumin, ethacrynic acid and BSO)
had any effect on cell viability when used alone.
Effect of MRP inhibitors on etoposide resistance of A375
cells
To investigate the involvement of endogenous MRPs in the
etoposide resistance, cells were pretreated with MRP inhibitors
before exposure to antineoplastic agents. As shown in Table 3 and
Figure 4, sulfinpyrazone, an MRP1 selective inhibitor (Morrow
et al, 1998) and MK571, an MRP1 and 3 inhibitor (Gekeler et al,
1995), significantly increased (about five-fold and 9.5-fold,
respectively) the AS RNA-mediated etoposide sensitisation of
doxycycline-treated A375-ASPi1
(þ) cells; these compounds in-
duced a stronger increase (up to 17-fold and 32-fold, respectively)
of the etoposide sensitivity of A375 cells in the absence of
doxycycline. None of the inhibitors used had any effect on cell
viability when used alone.
These data, suggesting a combined implication of GSTP1 and
MRP1 in the detoxification process of etoposide were confirmed by
coincubating A375 cells in the presence of GSTP1 and MRP1
inhibitors (ethacrynic acid and MK571, respectively). The associa-
tion of ethacrynic acid and MK571 significantly improved the
etoposide sensitisation of A375-ASPi1 cells mediated by each
inhibitor when used alone (about 3.5-fold and two-fold, respec-
tively) (Table 3 and Figure 4).
Requirement of GSTP1 and MRP1 in [
3H]-etoposide
accumulation
To confirm the involvement of functional GSTP1 and MRP1 in the
observed resistance of A375 melanoma cell to etoposide, we
studied the effects of GSTP1 AS RNA expression, and of
pharmacological inhibitors (curcumin, ethacrynic acid, BSO,
sulfinpyrazone, MK571), on [
3H]-etoposide accumulation. As
shown in Figure 5, inhibition of GSTP1 expression by AS RNA
significantly increased (about 35%) the accumulation of [
3H]-
etoposide in A375-ASPi1 cells. The involvement of functional GST
in this effect was confirmed by using curcumin, ethacrynic acid
and BSO, which significantly increased the accumulation of the
tritiated compound in the cell lines. Moreover, MRP1 inhibitors
(sulphinpyrazone, MK571) significantly increased the [
3H]-etopo-
side accumulation in A375-ASPi1 cells.
DISCUSSION
Malignant melanoma is a very chemoresistant tumour, which
expresses, in 100% of individuals, high level of GSTP1 (Moral et al,
1997) and, in about 50% of melanoma specimens, high level of
MRP1 (Schadendorf et al, 1995b). However, even if GSTP1
(Townsend and Tew, 2003) and MRP1 (Kruh and Belinsky, 2003)
have been implicated, sometimes in a coordinated fashion
(Harbottle et al, 2001), in the development of resistance toward
chemotherapy agents, only a few studies have investigated their
role in the drug resistance of MM and the results remained
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Figure 4 Effects of GSTP1 and MRP inhibition on the etoposide
sensitivity of A375 cell lines. A375-ASPi1 cells were preincubated in
presence (open symbols) or absence (closed symbols) of doxycycline
(0.2mgml
 1, 24h) and then exposed for 4h to etoposide alone (triangles)
or with 30mM MK571 (square), 3.3mM EA (circle) or 30mM
MK571þ3.3mM EA (diamond) as described under ‘Materials and Methods’.
Data are means7s.e.m. of three independent determinations.
Table 3 Effects of inhibitors of MRP (sulphinpyrazone, MK571), GST
(curcumin, ethacrynic acid) and GSH (BSO) on cellular sensitivities to
etoposide
Fold sensitisation to etoposide
Inhibitor A375-wt
( ) A375-ASPi1
( ) A375-ASPi1
(+)
Ethacrynic acid 19*** 18.4*** 5*
Curcumin 11*** 11.4*** 2.4*
BSO 21.3*** 22.6*** 6.8**
Sulfinpyrazone 18.1*** 17*** 5*
MK571 32*** 33.3*** 9.5**
Ethacrynic acid and MK571 ND 70*** 17.5***
Fold sensitisation¼IC50 of etoposide in the absence of inhibitor/IC50 of etoposide in
the presence of inhibitor. Ethacrynic acid, curcumin, BSO, sulphinpyrazone and
MK571 were used at 3.3mM,3 0mM,5 0mM,2m M and 30mM, respectively. Exponents
(+) and
( ) indicate that cells were pretreated in the presence or absence of
doxycycline, respectively. ND: not determined. Data are means from at least three
separate experiments. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test).
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Figure 5 Functional activity of MRP1 in A375-ASPi1 cell lines. Cells were
preincubated in presence (þ) or in absence ( ) of doxycycline
(0.2mgml
 1 24h). Then cells were incubated for 1h at 371C with 5mM
[
3H]-etoposide in culture medium. After washing with PBS, cells were
incubated at 371C for 3h in the absence (control) or presence of inhibitors
(2mM sulphinpyrazone (S), 30mM MK571 (MK), 30mM curcumin (C), 3.3mM
ethacrynic acid (EA)). For BSO 50mM (B), cells were preincubated 48h
before etoposide treatement. The intracellular [
3H]-etoposide concentra-
tion was evaluated by b-scintillation counting as described in ‘Materials and
Methods’. Data expressed as percentage of [
3H]-etoposide concentration
of control cells corresponding to A375-ASPi1 unexposed to inhibitors and
to doxycycline are means7s.e.m. of three separate experiments.
**Po0.01; ***Po0.001 according to Student’s t-test comparing values
obtained with inhibitor in cells with those obtained without inhibitor.
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scontradictory (Wang et al, 1989; Schadendorf et al, 1995a; Serrone
and Hersey, 1999; Ichihashi and Kitajima, 2001). In this paper, we
examined the effects of the inhibition of GSTP1 expression, by an
inducible AS RNA, on drug sensitivity of human melanoma A375
cells in relation with endogenous MRP proteins.
A375 cells were chosen because their expression profile of GSTs
and MRPs was similar to the expression profile of these
glutathione-related detoxifying enzymes in individual tumours.
In fact, as found in melanoma specimens (Schadendorf et al,
1995b; Moral et al, 1997), A375 cells expressed high levels of
GSTP1 and MRP1, whereas very lower levels of GSTM1 and MRP3
were detected. The controlled inhibition by AS RNA of GSTP1
expression in A375 cells was obtained using the Tet-Ont gene
expression system. A375 cells were successively transfected with
two expression vectors encoding either reverse rtTA or human
GSTP1 AS RNA, and selected for antibiotic resistance. The clone
A375-ASPi1, which displayed a specific 40% inhibition of GSTP1
expression and a significant decrease of total GST activity in the
presence of doxycycline (A375-ASPi1
(þ)) was selected for further
analysis. In fact, even if the inhibition of GSTP1 expression in
A375-ASPi1 cells by AS RNA was not complete, the observed
percentage (about 40%) was comparable to that (about 50%)
obtained in colon M7609 cells by using a retroviral expression
vector to transfect GSTP1 AS cDNA (Ban et al, 1996). As suggested
by Ban et al (1996), the degree of inhibition of gene expression by
AS nucleotides depends on many factors including the levels of
expression of the target gene as well as the amount of AS RNA
transcribed. Furthermore, the 40% lowering of GSTP1 expression
by AS RNA lasted for a time period (at least 7h) greater than that
(at the most 4h) chosen for anticancer drugs treatment in
cytotoxicity assays. Thus, A375-ASPi1 cells were a good model to
study the effect of GSTP1 inhibition by AS RNA, in relation with
endogenous MRPs, in MM chemoresistance. The cells expressing
GSTP1 AS RNA in the presence of doxycycline were named A375-
ASPi1
(þ). The control cells used were parental A375-wt cells and
the double transfectant ASPi1 clone in the absence of doxycycline
(A375-ASPi1
( )).
A possible involvement of GSTP1 in etoposide resistance of
human tumours was previously suggested by studies showing
either an elevated GSTP1 in many cell lines selected in the drug
(Tew, 1994) or a significantly influenced resistance by single
transfection of GSTP1 (O’Brien et al, 2000). By using an AS
approach, Ban et al (1996) observed a 2.1-fold increase of
etoposide sensitivity after a 50% inhibition of GSTP1 expression.
In A375 cells, a 40% reduction of GSTP1 expression level by
inducible AS RNA was enough to induce a similar (about three-
fold) increase of the etoposide sensitivity. This result, suggesting
the involvement of GSTP1 in the resistance of MM to this
topoisomerase II inhibitor, was confirmed by using pharmacolo-
gical tools. The requirement of functional GSTs was shown
by using the GST inhibitors curcumin and ethacrynic acid,
which significantly reinforced the sensitising effect of GSTP1AS
RNA in A375-ASPi1
(þ) cells, and also strongly improved the
etoposide sensitivity of A375-wt and A375-ASPi1
( ) control cells.
The glutathione-dependency of the epipodophyllotoxin resistance
of A375 cells was demonstrated by using BSO, an inhibitor of
glutathione synthesis, which significantly increased the sensitivity
of the cell lines to this agent. Taken together, these data strongly
suggested a relationship between GSTP1 expression level and
etoposide resistance of human melanoma. However, glutathione
conjugates of etoposide have not been described and the molecular
mechanism of the GSTP1-mediated protection remains unclear.
A plausible protective role of GSTP1 could be, as suggested
(O’Brien et al, 2000), a direct detoxification of quinone and
semiquinone metabolites of etoposide, the latter forming con-
jugates with GSH, or of hydroxyl radicals generated from this
metabolism. In favour of this hypothesis, it has been shown that
these reactive forms could be produced by tyrosinases in
melanoma cells and that toxicity of etoposide depended on
presence of tyrosinase (Usui and Sinha, 1990). Alternatively,
GSTP1 could act, as reported for inhibition of transcriptional
activation by the peroxisomal proliferator-activated receptor
gamma ligand, 15-deoxy-Delta(12,14)prostaglandin J(2) (Paumi
et al, 2004), by sequestering etoposide in the cytosol away from its
nuclear target.
Etoposide is a drug of the multidrug resistance phenotype
(MDR) and the two MRP isoforms expressed in A375 cells, MRP1
and MRP3, were previously found to be implicated in etoposide
resistance (Cole et al, 1994; Kool et al, 1999; Zeng et al, 1999;
Zelcer et al, 2001). This finding was confirmed by using the MRP
inhibitors sulfinpyrazone and MK571, which significantly in-
creased the [
3H]-etoposide accumulation and reduced the etopo-
side resistance of A375 cells. Considering that MRP3 on one hand
is expressed at a very low level in A375 cells, on the other hand is
only able to confer low levels of resistance to etoposide when
ectopically expressed in cell lines (Zelcer et al, 2001), it is likely to
assume that the MRP isoform mainly involved in A375 resistance
to this natural product agent was MRP1. Furthermore, a significant
increase of [
3H]-etoposide accumulation in A375 cell lines was
mediated by inhibition of GSTP1 expression (AS RNA), GST
activity (curcumin and ethacrynic acid) or glutathione synthesis
(BSO). The sensitising effect of the MRP inhibitors was stronger in
cells expressing high GSTP1 level (A375-ASPi1
( )cells) than in cells
expressing reduced GSTP1 level (A375-ASPi1
(þ)cells). Thus, as
reported from nontumoral cells (O’Brien et al, 2000) the efficacy of
the MRP1-mediated protection against etoposide was improved by
the expression of functional GSTP1 in human melanoma A375
cells. A possible mechanism could be the implication of the
glutathione metabolism in the export of etoposide from resistant
cancer cells via MRP1. In fact, even if GS-conjugates have not
been described, etoposide was shown to increase GSH export from
cells expressing MRP1, suggesting cotransport with GSH (Rappa
et al, 1997).
The sensitivity of the A375 cells to the other anticancer drugs
tested in this study (doxorubicin, chlorambucil, melphalan,
vincristine, cisplatin and mitoxantrone) was not affected by the
40% reduction of the GSTP1 expression level by AS RNA,
indicating either that GSTP1 is not related to the resistance to
these drugs, or that the degree of GSTPi1 inhibition is not
sufficient to increase efficiently the drug sensitivity of the cells.
This result is contradictory with previous Ban et al’s (1996) work,
showing an increased sensitivity to etoposide, and also to
doxorubicin, cisplatin and melphalan of colon M7609 after a
similar half lowering of GSTPi1 intracellular level by AS
transfection. However, it is in accordance with other studies
reporting the lack of correlation between GSTP1 expression level
and the sensitivity of different cancer cell lines to the drugs
mentioned above (Fairchild et al, 1990; Morrow et al, 1998;
Wang et al, 1999). Our explanation for this discrepancy is that
the detoxification processes seems to be highly specific on one
hand for the drug/GST isozyme/MRP isozyme combination, on the
other hand for the cell or tissue concerned. This hypothesis is
supported by recent investigations suggesting that the effects of
GSTs and/or MRPs expression on anticancer drug toxicity depend
on the cell type (Morrow et al, 1998; Harbottle et al, 2001; Depeille
et al, 2004).
In conclusion, we report a combined action of GSTP1 and MRP1
in the protection of A375 melanoma cells from etoposide effect.
These data provide rationale for studying the relationship between
the expression levels of GSTP1 and MRP1 in MM tumours and the
clinical outcome of patients treated with etoposide. In contrast, the
absence of effect of GSTP1 inhibition against the other agents
tested (doxorubicin, chlorambucil, melphalan, vincristine, cispla-
tin and mitoxantrone) strongly supports the finding that the action
of detoxification processes is very dependent on the tissue
concerned.
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